Fig. 1.
Cross-reactivity between A*0201+viral peptide and allogeneic cells.
VP13/14-specific CD8 CTL clones derived from genital HSV-2 lesions were used as effector cells against EBV-LCL targets. Target cells from patient 5101 only were tested after infection with HSV-2. Results are representative of at least 2 experiments for each effector and target cell combination.